The mitotic spindle assembly checkpoint (SAC) delays anaphase onset until all chromosomes have attached to both spindle poles 1,2 . Here, we investigated SAC signaling kinetics in response to acute detachment of individual chromosomes using laser microsurgery. Most detached chromosomes delayed anaphase until they had realigned to the metaphase plate. A substantial fraction of cells, however, entered anaphase in the presence of unaligned chromosomes. We identify two mechanisms by which cells can bypass the SAC: First, single unattached chromosomes inhibit the anaphase promoting complex/cyclosome (APC/C) less efficiently than a full complement of unattached chromosomes. Second, because of the relatively slow kinetics of reimposing APC/C inhibition during metaphase, cells were unresponsive to chromosome detachment up to several minutes before anaphase onset. Our study defines when cells irreversibly commit to enter anaphase and shows that the SAC signal strength correlates with the number of unattached chromosomes. Detailed knowledge about SAC signaling kinetics is important for understanding the emergence of aneuploidy and the response of cancer cells to chemotherapeutics targeting the mitotic spindle.Spindle assembly is an error prone process, which can involve multiple rounds of microtubule attachment and detachment on individual kinetochores 3,4 . Incorrectly attached chromosomes, for example when both sister kinetochores bind to the same spindle pole, are detected by an error correction machinery, which depolymerizes microtubules on kinetochores if they are under low mechanical tension (reviewed in 5 ). This enables chromosomes to eventually attach their sister kinetochores to microtubules originating from opposing spindle poles.Due to the stochastic nature of spindle assembly, anaphase must be robustly delayed when individual chromosomes fail to attach properly. Indeed, a single unattached kinetochore can delay anaphase onset for up to several hours in PtK 1 cells 6 . Yet, even when all kinetochores are unattached by drug-induced depolymerization of microtubules, cyclin B continues to be degraded by low residual APC/C activity, which leads to mitotic exit in presence of an * Address correspondence to DWG. daniel.gerlich@imba.oeaw.ac.at. Author contributions: A.E.D. designed and conducted experiments and analyzed data. D.W.G. conceived the project, analyzed data, and wrote the manuscript with help by A.E.D. Competing financial interests:The authors declare no competing financial interests. [7][8][9] . Mitotic slippage occurs at different rates in a variety of cancer and non-cancer cells and it has been proposed as a mechanism by which cancer cells may develop resistance against therapeutics that target the mitotic spindle [8][9][10][11][12] . Hence, it is important to better understand the signaling kinetics underlying SAC-mediated APC/C inhibition. Europe PMC Funders GroupUnattached kinetochores recruit the SAC protein Mad2 to promote assembly of cytoplasmic mitotic checkpoint complex, composed of Ma...

Objective. DEK is a nuclear phosphoprotein and autoantigen in a subset of children with juvenile idiopathic arthritis (JIA). Autoantibodies to DEK are also found in a broad spectrum of disorders associated with abnormal immune activation. We previously demonstrated that DEK is secreted by macrophages, is released by apoptotic T cells, and attracts leukocytes.Since DEK has been identified in the synovial fluid (SF) of patients with JIA, this study was undertaken to investigate how DEK protein and/or autoantibodies may contribute to the pathogenesis of JIA.Methods. DEK autoantibodies, immune complexes (ICs), and synovial macrophages were purified from the SF of patients with JIA. DEK autoantibodies and ICs were purified by affinity-column chromatography and analyzed by 2-dimensional gel electrophoresis, immunoblotting, and enzyme-linked immunosorbent assay. DEK in supernatants and exosomes was purified by serial centrifugation and immunoprecipitation with magnetic beads, and posttranslational modifications of DEK were identified by nano-liquid chromatography tandem mass spectrometry (nano-LC-MS/MS).Results. DEK autoantibodies and protein were found in the SF of patients with JIA. Secretion of DEK by synovial macrophages was observed both in a free form and via exosomes. DEK autoantibodies (IgG2) may activate the complement cascade, primarily recognize the C-terminal portion of DEK protein, and exhibit higher affinity for acetylated DEK. Consistent with these observations, DEK underwent acetylation on an unprecedented number of lysine residues, as demonstrated by nano-LC-MS/MS.Conclusion. These results indicate that DEK can contribute directly to joint inflammation in JIA by generating ICs through high-affinity interaction between DEK and DEK autoantibodies, a process enhanced by acetylation of DEK in the inflamed joint.Juvenile idiopathic arthritis (JIA), a polymorphic chronic inflammatory disease of unknown etiology, is

SummaryTwo mechanisms safeguard the bipolar attachment of chromosomes in mitosis. A correction mechanism destabilizes erroneous attachments that do not generate tension across sister kinetochores [1]. In response to unattached kinetochores, the mitotic checkpoint delays anaphase onset by inhibiting the anaphase-promoting complex/cyclosome (APC/CCdc20) [2]. Upon satisfaction of both pathways, the APC/CCdc20 elicits the degradation of securin and cyclin B [3]. This liberates separase triggering sister chromatid disjunction and inactivates cyclin-dependent kinase 1 (Cdk1) causing mitotic exit. How eukaryotic cells avoid the engagement of attachment monitoring mechanisms when sister chromatids split and tension is lost at anaphase is poorly understood [4]. Here we show that Cdk1 inactivation disables mitotic checkpoint surveillance at anaphase onset in human cells. Preventing cyclin B1 proteolysis at the time of sister chromatid disjunction destabilizes kinetochore-microtubule attachments and triggers the engagement of the mitotic checkpoint. As a consequence, mitotic checkpoint proteins accumulate at anaphase kinetochores, the APC/CCdc20 is inhibited, and securin reaccumulates. Conversely, acute pharmacological inhibition of Cdk1 abrogates the engagement and maintenance of the mitotic checkpoint upon microtubule depolymerization. We propose that the simultaneous destruction of securin and cyclin B elicited by the APC/CCdc20 couples chromosome segregation to the dissolution of attachment monitoring mechanisms during mitotic exit.

Poly(ADP-ribose) polymerases (PARPs) regulate various aspects of cellular function including mitotic progression. Although PARP inhibitors have been undergoing various clinical trials and the PARP1/2 inhibitor olaparib was approved as monotherapy for BRCA-mutated ovarian cancer, their mode of action in killing tumour cells is not fully understood. We investigated the effect of PARP inhibition on mitosis in cancerous (cervical, ovary, breast and osteosarcoma) and non-cancerous cells by live-cell imaging. The clinically relevant inhibitor olaparib induced strong perturbations in mitosis, including problems with chromosome alignment at the metaphase plate, anaphase delay, and premature loss of cohesion (cohesion fatigue) after a prolonged metaphase arrest, resulting in sister chromatid scattering. PARP1 and PARP2 depletion suppressed the phenotype while PARP2 overexpression enhanced it, suggesting that olaparib-bound PARP1 and PARP2 rather than the lack of catalytic activity causes this phenotype. Olaparib-induced mitotic chromatid scattering was observed in various cancer cell lines with increased protein levels of PARP1 and PARP2, but not in non-cancer or cancer cell lines that expressed lower levels of PARP1 or PARP2. Interestingly, the sister chromatid scattering phenotype occurred only when olaparib was added during the S-phase preceding mitosis, suggesting that PARP1 and PARP2 entrapment at replication forks impairs sister chromatid cohesion. Clinically relevant DNA-damaging agents that impair replication progression such as topoisomerase inhibitors and cisplatin were also found to induce sister chromatid scattering and metaphase plate alignment problems, suggesting that these mitotic phenotypes are a common outcome of replication perturbation.

Although it has been decades since PARP inhibitors were initially discovered and various clinical trials have been performed, their mode of action in killing tumor cells subsequent to PARP inhibition is still not fully understood. We have recently identified poly(ADP-ribosyl)ation (PARylation) as a new post-translational modification of the cohesin complex, a key player in chromosome segregation during mitosis. We investigated the effect of PARP inhibition on mitosis in a panel of cells of cancer (cervical, breast, ovarian) and normal tissue origin. We treated cancerous and non-cancerous cell lines labelled with chromatin markers with a selected set of PARP inhibitors and imaged them with fluorescence live microscopy. Out of 5 tested inhibitors, a well-known and clinically relevant PARP inhibitor olaparib, induced strongest perturbations in mitotic progression. Olaparib induced a delay in entering anaphase, problems aligning chromosomes at the metaphase plate and premature loss of cohesion (cohesion fatigue) after a prolonged metaphase arrest. Cohesion fatigue, leading to cell death, was observed in cancer cell lines exhibiting S-phase stalling or G2/M arrest with increased protein levels of PARP1. Olaparib is known to entrap PARP1 at replication forks and thereby perturb replication fork movement. While its addition before the onset of mitosis did not result in mitotic defects, addition of olaparib only in S-phase was sufficient to cause mitotic phenotypes. Our results indicate that PARP inhibition by olaparib in S phase has downstream effects on mitotic progression. PARP1 RNAi in addition to olaparib treatment rescues the cohesion fatigue phenotype, suggesting that entrapment of PARP1 at the replication fork upon its inhibition is the main cause of cohesion fatigue. Cohesion fatigue was observed only in highly aneuploid cancer cells that are described to have an increased rate of chromosome mis-segregation. In conclusion, higher susceptibility of aneuploid cancer to cohesion fatigue and cell death upon olaparib treatment relative to normal cells would support its use as anti-mitotic chemotherapy. Citation Format: Eva Kukolj, Tanja Kaufmann, Amalie E. Dick, Robert Zeillinger, Daniel W. Gerlich, Dea Slade. Olaparib causes premature loss of cohesion in cancer cells. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr A35.

Poly(ADP-ribose) polymerases (PARPs) regulate various aspects of cellular function including mitotic progression. Although PARP inhibitors have been undergoing various clinical trials and the PARP1/2 inhibitor olaparib was approved as monotherapy for BRCA-mutated ovarian cancer, their mode of action in killing tumour cells is not fully understood. We investigated the effect of PARP inhibition on mitosis in cancerous (cervical, ovary, breast and osteosarcoma) and noncancerous cells by live-cell imaging. The clinically relevant inhibitor olaparib induced strong perturbations in mitosis, including problems with chromosome alignment at the metaphase plate, anaphase delay, and premature loss of cohesion (cohesion fatigue) after a prolonged metaphase arrest, resulting in sister chromatid scattering. PARP1 and PARP2 depletion suppressed the phenotype while PARP2 overexpression enhanced it, suggesting that olaparib-bound PARP1 and PARP2 rather than the lack of catalytic activity causes this phenotype. Olaparib-induced mitotic chromatid scattering was observed in various cancer cell lines with increased protein levels of PARP1 and PARP2, but not in non-cancer or cancer cell lines that expressed lower levels of PARP1 or PARP2. Interestingly, the sister chromatid scattering phenotype occurred only when olaparib was added during the S-phase preceding mitosis, suggesting that PARP1 and PARP2 entrapment at replication forks impairs sister chromatid cohesion. Clinically relevant DNA-damaging agents that impair replication progression such as topoisomerase inhibitors and cisplatin were also found to induce sister chromatid scattering and metaphase plate alignment problems, suggesting that these mitotic phenotypes are a common outcome of replication perturbation. topoisomerase inhibitors (camptothecin, etoposide) and cisplatin, suggesting that death by mitotic failure is a general phenomenon of perturbed replication. RESULTS Olaparib causes anaphase delay and chromatid scattering in metaphase-arrested cellsIn order to investigate the effect of PARP inhibition on mitosis, we performed live-cell imaging of HeLa cells stably expressing H2B-mCherry together with securin-EGFP [29] treated with olaparib (AZD2281, Ku-0059436) [30], talazoparib (BMN 673) [31] or veliparib (ABT-888) [32] as PARP1/2 inhibitors, XAV-939 as tankyrase1/2 (PARP5a/b) inhibitor [33] and ME328 as PARP3 inhibitor ( Figure 1A) [34]. Of the five tested inhibitors applied at different concentrations for 30 h, only PARP1/2 inhibitors caused anaphase delay measured as the time required for the cells to progress from nuclear envelope breakdown (NEBD) to anaphase (Figure 1A,B). The median NEBD-anaphase duration was extended from 42 min in DMSO-treated control cells to 57 min for 10 μ M olaparibtreated cells, to 60 min for 30 μ M veliparib and to 60 min for 100 nM talazoparib (Figure 1A,B). 40-50% of inhibitor-treated mitotic cells failed to enter anaphase due to metaphase plate formation problems or chromatid scattering after correct metaphase plate formation ( Figure 1B...